# Switch to TAF+FTC+BIC in HIV-1-infected Patients Over 65 Years Old at Risk of Polymedication

> **NCT04222283** · PHASE4 · UNKNOWN · sponsor: **Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba** · enrollment: 27 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** BIKTARVY 50Mg-200Mg-25Mg Tablet

## Key facts

- **NCT ID:** NCT04222283
- **Lead sponsor:** Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-17
- **Primary completion:** 2021-12-20
- **Final completion:** 2022-06-30
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2022-06-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04222283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04222283, "Switch to TAF+FTC+BIC in HIV-1-infected Patients Over 65 Years Old at Risk of Polymedication". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04222283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*